STRIDE (durvalumab + tremelimumab)

DRUG2 trials

Sponsors

Canadian Cancer Trials Group, Riboscience, LLC.

Conditions

Advanced Unresectable Hepatocellular CarcinomaHepatocellular Carcinoma

Phase 2

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

RecruitingNCT06880523

Canadian Cancer Trials GroupHepatocellular Carcinoma

Start: 2025-10-21End: 2028-12-31Target: 140Updated: 2026-08-11

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

RecruitingNCT07175441

Riboscience, LLC.Advanced Unresectable Hepatocellular Carcinoma

Start: 2026-04-10End: 2027-08-01Target: 220Updated: 2026-04-24